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INTRODUCTION
Oxidative stress is currently suggested
to be a mechanism underlying diabetes and
diabetic complications [1]. Reactive oxy-
gen species (ROS)† are generated in bio-
logical systems through metabolic process-
es and through exogenous sources such as
food components, drugs, ultraviolet light,
ionizing radiation, and air pollution [2].
Under physiological conditions, a wide
range of antioxidant defenses protects
against the adverse effects of free radical
production in vivo [2]. The chronic hyper-
glycaemia in diabetes enhances the pro-
duction of ROS from glucose oxidation,
protein glycation and glycoxidation [3].
In diabetes, protein glycation and glu-
cose oxidation may generate free radicals,
which, in turn, cause lipid peroxidation [4].
Moreover, ROS have also been implicated
in the mechanism of damage to the red
blood cells (RBC) [5].The concentration of
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Oxidative stress is currently hypothesized to be a mechanism underlying diabetes. The pre-
sent study was designed to evaluate the effect of umbelliferone (UMB), a derivative of
coumarin, on erythrocyte lipid peroxidation, antioxidants, and lipid profile in normal and
streptozotocin (STZ) diabetic rats. Diabetes was induced in adult male albino rats of Wistar
strain, weighing 180 to 200 g, by the administration of STZ (40 mg/kg/b-wt) intraperitonial-
ly. The normal and diabetic rats were treated with UMB in 10 percent dimethyl sulfoxide
(DMSO) dissolved in water for 45 days. The diabetic rats had elevated levels of blood glu-
cose and lipid peroxidation markers such as thiobarbituric acid reactive substances
(TBARS), conjugated dienes (CD), and lipid hydroperoxide (HP) and decreased levels of
nonenzymatic antioxidants (Vitamin C and reduced glutathione [GSH]),elevated levels of vit-
amin E, and elevated levels of enzymatic antioxidants (superoxide dismutase [SOD], cata-
lase [CAT], glutathione peroxidase [GPx]), elevated glucose-6-phosphate dehydrogenase
activity, and altered lipid profile (cholesterol and phospholipids) in erythrocytes. These
changes were reversed by treatment with UMB. Thus, our results indicate that the adminis-
tration of UMB shows promising potential for the restoration of normal blood glucose levels,
erythrocyte lipid peroxidation, antioxidants, and lipid profile in STZ-diabetic rats.ROS is modulated by antioxidant enzymes
such as SOD, CAT, and GPx, and by
nonenzymatic antioxidants such as GSH
[6]. In diabetes, oxidative stress seems to
be caused by increased production of ROS,
a sharp reduction in antioxidant defenses,
and altered cellular redox status [7]. In
addition to endogenous mechanisms of
quenching ROS, much attention has been
focused on the antioxidative roles of many
plant extracts. Plant products are consid-
ered to be less toxic and freer from side-
effects than synthetic ones [8].
Umbelliferone (7-hydroxycoumarin),
a derivative of coumarin, is a benzopyrone
present in the fruits and roots of Anethum
graveolens L and the roots of Ruta grave-
olens L c9-11. It was noted that several
plant-derived phenolic coumarins might
play a role as dietary antioxidants through
their consumption in the human diet in
fruits and vegetables; UMB has been
reported to have antioxidant properties
[12]. The parent compound coumarin has
been reported to reduce blood glucose
level [13]. Coumarin may be a prodrug for
which 7-hydroxycoumarin is the pharma-
cologically active agent [14]. Our prelim-
inary studies showed that treatment with
UMB effectively reduced blood glucose
levels in diabetic rats [15], but no detailed
study has been carried out on the effect of
UMB on erythrocyte redox status in the
diabetic condition. Hence, the present
study was designed to investigate the
effect of UMB on lipid peroxidation,
antioxidants and lipid profile in erythro-
cytes of STZ-diabetic rats. The structure
of UMB is depicted in Figure 1.
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MATERIALS AND METHODS
Animals
Male albino(9-week-old) rats ofWistar
strain with a body weight ranging from 180
to 200 g, were procured from Central
AnimalHouse,DepartmentofExperimental
Medicine, Rajah Muthiah Medical College
and Hospital, Annamalai University, and
weremaintainedinanair-conditionedroom
(25 ± 1°C) with a 12 h light/12 h dark cycle.
Feed and water were provided ad libitum to
all the animals. All studies were conducted
in accordance with National Institutes of
Health Guide for the Care and Use of
Laboratory Animals [15] and the study was
approvedbytheEthicalCommitteeofRajah
MuthiahMedicalCollegeandHospital(Reg
No.160/1999/CPCSEA), Annamalai
University,Annamalainagar.
Chemicals
Streptozotocin was purchased from
Sigma-Aldrich (St. Louis, Missouri,
United States). UMB was procured from
Carl Roth GmbH and Company
(Germany).All the other chemicals used in
our study were of analytical grade obtained
from E. Merck and HIMEDIA (India).
Experimental induction of diabetes
The animals were rendered diabetic
by a single intraperitoneal injection of STZ
(40 mg/kg/b.wt) in freshly prepared citrate
buffer (0.1 M, pH 4.5) after an overnight
fast. STZ injected animals were given 20
percent glucose solution for 24 hours to
prevent initial drug-induced hypogly-
caemic mortality. STZ-injected animals
exhibited massive glycosuria (determined
by Benedict’s qualitative test) and hyper-
glycaemia (by glucose oxidase method)
within a few days. Diabetes in STZ rats
was confirmed by measuring the fasting
blood glucose concentration 96 hours after
injection with STZ. The animals with
blood glucose above 235 mg/dl were con-
sidered to be diabetic and used for the
experiment. Figure 1. Structure of UMB.Experimental design
The animals were randomly divided
into five groups of six animals described
below. The UMB and glibenclamide were
administered intraperitoneally using a
vehicle solution (10 percent DMSO).
Group I: Normal control (10 percent DMSO)
Group II: Normal + UMB (30 mg/kg/b.wt in
10 percent DMSO)
Group III: Diabetic control (10 percent
DMSO)
Group IV: Diabetic + UMB (30 mg/kg/b.wt
in 10 percent DMSO)
Group V: Diabetic + glibenclamide (600
µg/kg b.wt in 10 percent DMSO)
After 45 days of treatment, the ani-
mals were fasted for 12 hours, anaes-
thetized between 8:00 a.m. to 9:00 a.m.
using ketamine (24 mg/kg/b.wt, intramus-
cular injection), and sacrificed by cervical
decapitation. Blood was collected in tubes
with a mixture of potassium oxalate and
sodium fluoride (1:3) for the estimation of
blood glucose. The buffy coat was
removed, and the erythrocytes were
washed three times with physiological
saline. Aliquots of erythrocytes were kept
at 4°C until analysis.
Biochemical analysis
Blood glucose was estimated by the
method of Trinder et al. [16]. Erythrocyte
TBARS, HP, and CD were estimated by the
methods of Nichans and Samuelson [17],
Jiang et al. [18], and Klein [19], respective-
ly. The nonenzymic antioxidants, GSH, vit-
amins C and E were estimated by the meth-
ods of Ellman [20], Roe and Kuether [21],
and Baker and Frank [22], respectively.The
activities of SOD, CAT, GPx, glucose-6-
phosphate dehydrogenase, and the levels of
cholesterol and phospholipids were mea-
sured by the methods of Kakkar et al. [23],
Sinha [24], Rotruck et al. [25], Bergmeyer
[26], Siedel et al. [27], and Zilversmit and
Davis [28], respectively.
Statistics
Values are given as means ± SD for
six rats in each group. Data were analysed
by one way analysis of variance (ANOVA)
followed by Duncan’s Multiple Range
Test (DMRT) using SPSS-10. The limit of
statistical significance was set at p < .05.
RESULTS
Table 1 illustrates the effect of UMB
on blood glucose in diabetic rats. Blood
glucose was significantly elevated in dia-
betic rats as compared with normal control
rats. In UMB and glibenclamide-treated
rats, the blood glucose was reversed to near
normal level when compared with diabetic
control rats. The changes in the levels of
TBARS, HP, and CD in the erythrocytes of
normal and diabetic rats are given in the
Table 2. Diabetic rats had elevated levels of
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Table 1. Effect of UMB on blood glucose in diabetic rats.
Blood glucose (mg/dl)
Group 0 day 45th day
Normal control 79.60 ﾱ 5.25 82.44 ﾱ 2.68b
Normal + UMB (30 mg/kg/b.wt) 82.14 ﾱ 3.19 74.29 ﾱ 4.17a
Diabetic control 240.47 ﾱ 5.82 289.28 ﾱ 3.18d
Diabetic + UMB (30 mg/kg/b.wt) 244.63 ﾱ 6.29 114.28 ﾱ 5.71c
Diabetic + glibenclamide (600 ﾵg/kg/b.wt) 242.85 ﾱ 5.04 107.23 ﾱ 7.23c
Values are given as means ﾱ SD from six rats in each group. Values not sharing a com-
mon superscript differ significantly at p < .05 (DMRT).Table 3. Effect of UMB on enzymic antioxidants in erythrocytes of diabetic rats.
Hemolysate
SOD CAT GPx
Group (U*/mg Hb) (U**/mg Hb) (U***/mg Hb)
Normal control 7.50 ﾱ .54 176.09 ﾱ 11.03b 14.75 ﾱ 1.04b
Normal + UMB
(30 mg/kg/b.wt) 8.17 ﾱ 1.18a 189.86 ﾱ 7.72a 16.6 ﾱ .78a
Diabetic control 3.52 ﾱ .66e 100.54 ﾱ 9.52d 8.45 ﾱ .69d
Diabetic + UMB 6.15 ﾱ .78c 157.20 ﾱ 4.90c 13.4 ﾱ .61c
(30 mg/kg/b.wt)
Diabetic + glibenclamide 6.75 ﾱ .50c 164.97 ﾱ 7.81c 14.15 ﾱ .91b,c
(600 ﾵg/kg/b.wt)
Values are given as means ﾱ SD from six rats in each group. Values not sharing a com-
mon superscript differ significantly at p < .05 (DMRT). *One unit of SOD is defined as the
enzyme reaction, which gives 50 percent inhibition of NBT reduction in one minute. **One
unit of CAT is defined as the ﾵ mole of hydrogen peroxide consumed per minute.***One
unit of GPx is defined as the ﾵg of glutathione consumed per minute.
TBARS, HP, and CD in erythrocytes as
compared with normal control rats.
Diabetic rats treated with UMB and gliben-
clamide brought backTBARS, HP, and CD
to near normal levels.
The levels of nonenzymatic, enzymat-
ic antioxidants, and glucose-6-phosphate
dehydrogenase in erythrocytes of normal
and diabetic rats are represented in Tables
3 and 4. Diabetic rats showed a significant
decrease in erythrocyte levels of vitamin
C, GSH, SOD, CAT, GPx, and glucose-6-
phosphate dehydrogenase and an increase
in vitamin E levels as compared to normal
control rats. Diabetic rats treated with
UMB and glibenclamide showed a rever-
sal of erythrocyte vitamin E and vitamin
C, GSH, and SOD, CAT, GPx, and glu-
cose-6-phosphate dehydrogenase levels
when compared to diabetic control rats.
The levels of cholesterol and phos-
pholipids in erythrocytes of normal and
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Table 2. Effect of UMB on lipid peroxidation markers in erythrocytes of diabetic rats.
Haemolysate
TBARS HP CD
Group ( nmol/mg protein) (ﾵmol/mg (Ratio of
protein) 240/214 nm )
Normal control 1.93 ﾱ .13b 1.15 ﾱ .09b 0.72 ﾱ .05b
Normal+UMB
(30 mg/kg/b.wt) 1.72 ﾱ .07a .085 ﾱ .05a 0.66 ﾱ .04a
Diabetic control 4.67 ﾱ .32e 1.38 ﾱ .07d 0.87 ﾱ .07d
Diabetic+ UMB
(30 mg/kg/b.wt) 2.83 ﾱ .23d 1.24 ﾱ .04c 0.78 ﾱ .03c
Diabetic+ glibenclamide
(600 ﾵg/kg b.wt.) 2.39 ﾱ .11c 1.21 ﾱ .04c 0.75 ﾱ .04b,c
Values are given as means ﾱ SD from six rats in each group. Values not sharing a com-
mon superscript vertically differ significantly at p < 0.05 (DMRT).diabetic rats are represented in Table 5.
Diabetic control rats had decreased levels
of cholesterol and phospholipids in ery-
throcytes. Treatment with UMB and
glibenclamide brought back cholesterol
and phospholipids levels to near normal
levels as compared with the diabetic con-
trol rats.
DISCUSSION
In an earlier report, coumarin was
reported to reduce blood glucose levels
[13]. In our study, diabetic rats treated
with UMB brought blood glucose level to
near normal level. A possible mechanism
by which UMB brings about its antihyper-
glycaemic effect is through the elevation
of plasma insulin levels.
The tremendous increase in lipid per-
oxidation in erythrocytes observed in dia-
betic rats is attributed to chronic hypergly-
caemia, which causes increased produc-
tion of ROS due to autooxidation of mono-
saccharides, which leads to the production
of superoxide and hydroxyl radicals. This,
in turn, causes tissue damage by reacting
with polyunsaturated fatty acids in mem-
brane [30, 31]. It was noted that several of
the plant-derived phenolic coumarins
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Table 4. Effect of UMB on nonenzymatic antioxidants and glucose-6-phosphate
dehydrogenase in erythrocytes of diabetic rats.
Hemolysate
Glucose-6
phosphate
Vitamin C Vitamin E dehydrogenase
Group (ﾵg/mg of Hb) (ﾵg/mg of Hb) GSH (mg/dl) (IU/g Hb)
Normal control 1.85 ﾱ .03b 1.18 ﾱ .08b 75.76 ﾱ 3.71b 4.65 ﾱ .31b
Normal + UMB
(30 mg/kg/b.wt) 2.16 ﾱ .01a 1.39 ﾱ .02a 80.26 ﾱ 3.84a 5.85 ﾱ .42a
Diabetic control 0.95 ﾱ .06d 2.74 ﾱ .09e 48.53 ﾱ 4.37e 3.1 ﾱ .36d
Diabetic + UMB 1.73 ﾱ .02c 1.52 ﾱ .10e 63.2 ﾱ 2.42d 4.25 ﾱ .35c
(30 mg/kg/b.wt)
Diabetic + glibenclamide 1.78 ﾱ .03c 1.43 ﾱ .08c 67.73 ﾱ 2.5c 4.55 ﾱ .29c
(600 g/kg/b.wt)
Values are given as means ﾱ SD from six rats in each group. Values not sharing a com-
mon superscript differ significantly at p < .05 (DMRT).
Table 5. Effect of UMB on cholesterol and phospholipids in erythrocytes
of diabetic rats.
Hemolysate
Group Cholesterol Phospholipids
(ﾵg/mg protein) (ﾵg/mg protein)
Normal control 148.5 ﾱ 7.19b 294.82 ﾱ 17.08b
Normal + UMB (30 mg/kg/b.wt) 165.16 ﾱ 5.16a 314.07 ﾱ 17.70a
Diabetic control 108.16 ﾱ 6.73d 221.72 ﾱ 21.13d
Diabetic + UMB (30 mg/kg/b.wt) 137.86 ﾱ 6.62c 275.54 ﾱ 26.23c
Diabetic + glibenclamide (600 mg/kg/b.wt) 141.16 ﾱ 8.26b,c 278.72 ﾱ 24.62c
Values are given as means ﾱ SD from six rats in each group. Values not sharing a com-
mon superscript differ significantly at p < .05 (DMRT).might play a role as dietary antioxidants
because of their consumption in the human
diet in fruits and vegetables, and UMB has
also been reported to have antioxidant an
property [12]. Diabetic rats treated with
UMB brought lipid peroxidation markers
back to near normal, which could be a
result of improved antioxidant status.
Oxidative stress in diabetes correlates
with a reduction in the antioxidant status
[32]. The antioxidants vitamins C and E
have been shown to reduce oxidative
stress in experimental diabetes [33]. In our
study, decreased vitamin C and increased
vitamin E are found in the erythrocytes of
diabetic rats. This is due to increased uti-
lization and increased membrane damage.
Since circulating RBCs act as a sink for
free radicals, both superoxide radicals and
hydrogen peroxide have the ability to pen-
etrate the membrane of the cells [34]. In
UMB-treated rats, the reversal of these
antioxidants is due to decreased peroxida-
tion of erythrocyte membrane.
Normally, the SOD enzyme works in
parallel with GPx, which plays an impor-
tant role in the reduction of hydrogen per-
oxides in the presence of GSH-forming
oxidized glutathione, (GSSG) thereby pro-
tecting cell protein and membrane from
oxidative stress [35].The erythrocyte SOD,
CAT, and GPx activities were decreased in
diabetic rats. These results are consistent
with the report of Skhra et al. [36]. In
UMB-treated rats, the reversal of activities
of these enzymes in erythrocytes is evi-
denced by decreased lipid peroxidation
markers and improved glycaemic control.
ROS are continuously generated in
physiological conditions and eliminated
by several intracellular and extracellular
antioxidant systems [37]. Decreased activ-
ity of antioxidant enzymes in uncontrolled
diabetes is due to decreased GSH forma-
tion, which requires NADPH and glu-
tathione reductase [38]. The reduced avail-
ability of NADPH could be due to reduced
synthesis in the HMP shunt due to
decreased activity of glucose-6-phosphate
dehydrogenase, which plays an important
role in the maintenance of the high
NADPH/NADP+ ratio in the cell and plays
a crucial role in the regeneration of GSH
from GSSG [39]. In UMB-treated rats, the
increased activity of glucose-6-phosphate
dehydrogenase is due to enhanced synthe-
sis caused by UMB. The NADPH generat-
ed could increase the concentration of
GSH observed in our study, which is, in
turn, utilized by GPx [40].
In our study, the reduction of TC in
erythrocytes of diabetic rats was observed,
as reported earlier [41]. The reduction in
membrane cholesterol content is known to
increase the disordering and hence alter the
fluidity of membrane [42]. The diabetic
rats treated with UMB reversed membrane
cholesterol to near normal, which could be
as a result of decreased lipid peroxidation.
Phospholipids are vital components of
biomembranes and play an important role
in the transport of triglycerides [43]. In our
study, the total phospholipid content of
erythrocytes was decreased in STZ-diabet-
ic rats, which is in agreement with Jain et
al. [44], who reported that choline contain-
ing phospholipids, which exists at the
outer side of the membrane, were not
altered, whereas the phosphatidyle-
thanolamine and phosphatidylserine exist-
ing at the inner side of the erythrocyte
membrane were reduced. This hypothesis
supports the idea that the phospholipid
fraction closer to the site of peroxidation
reaction was affected. The diabetic rats
treated with UMB have reversed the total
phospholipids of erythrocytes as a result of
reduced membrane lipid peroxidation.
CONCLUSION
Our results indicate that UMB has
exerted a rapid protective effect against
lipid peroxidation by scavenging free rad-
icals and elevating both nonenzymic and
enzymic antioxidants and thus alleviating
the adverse complications of diabetes mel-
litus.
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